What Does the Research Say About Bone Remodelling?

What is bone remodelling?

Bone remodelling is the continuous, coupled process by which osteoclasts resorb mineralised bone and osteoblasts deposit new bone matrix, maintaining skeletal integrity and calcium homeostasis. In the research literature it is also referred to as bone turnover or bone metabolism. The process is regulated by systemic hormones, local growth factors, and mechanical loading, and its dysregulation underlies conditions such as osteoporosis, a systemic skeletal disorder affecting approximately 10% of individuals over 50 years of age and characterised by an increased risk of fragility fractures [2].

At the molecular level, remodelling is controlled by the RANK/RANKL/OPG signalling axis and by the Wnt/β-catenin pathway, the latter modulated by sclerostin. Sclerostin inhibition is the mechanism of action of romosozumab, a dual-action agent that simultaneously stimulates osteoblast-mediated bone formation and inhibits osteoclast-driven bone resorption [2].

Research Studies

Vitamin K status and bone strength, geometry and microarchitecture

A prospective cross-sectional case-control study enrolled 108 patients undergoing arthroplasty (hip-fracture, n = 63; non-fracture, n = 45) and collected bone biopsies and blood specimens intraoperatively. The study examined the incremental contribution of six pathway-specific nutritional biomarkers, including circulating markers reflecting vitamin K, one-carbon metabolism, and antioxidant nutrients (vitamins E and C). The authors reported differential associations of osteocalcin carboxylation states with bone strength, geometry and microarchitecture, noting that most prior studies included participants with metabolic conditions that obscure nutrient-specific effects [1].

MicroRNA markers and therapeutic response to romosozumab and abaloparatide

An ongoing clinical study is investigating microRNA markers and therapeutic response to romosozumab and abaloparatide in postmenopausal osteoporosis. Approved pharmacological therapies for osteoporosis include anabolic agents that stimulate osteoblast-mediated bone formation (teriparatide, abaloparatide), antiresorptive agents that inhibit osteoclast-driven bone resorption (bisphosphonates, denosumab), and dual-action agents such as romosozumab [2]. The study aims to identify molecular markers associated with response to these agents.

Parathyroid hormone and maxillary sinus augmentation with xenograft

A clinical study is evaluating the combination of parathyroid hormone (PTH) with bovine-derived bone graft in maxillary sinus augmentation. The objective is to assess PTH's efficacy in bone regeneration and bone remodelling through radiological, clinical, biomarker, histological and histomorphometric assessment. Outcomes include evaluation of bone density at planned implant sites using cone beam computed tomography (CBCT) and histomorphometric examination of maxillary sinus bone to measure bone trabeculae, connective tissue, osteoblast and osteocyte populations after healing 4 months after grafting [3].

Comparison of bone remodelling markers across studies

Mechanistic insights from pharmacological agents

The mechanisms of bone remodelling are further illuminated by the actions of approved osteoporosis therapies. Anabolic agents such as teriparatide and abaloparatide stimulate osteoblast-mediated bone formation, while antiresorptive agents such as bisphosphonates and denosumab inhibit osteoclast-driven bone resorption. Romosozumab, through sclerostin inhibition, simultaneously stimulates formation and inhibits resorption [2]. These distinct mechanisms underscore the coupled nature of remodelling and the potential for therapeutic modulation.

Biomarkers of bone remodelling

Biomarkers reflecting vitamin K status, including osteocalcin carboxylation states, have been associated with bone strength, geometry and microarchitecture in patients undergoing arthroplasty [1]. In the maxillary sinus augmentation model, histomorphometric assessment measures bone trabeculae, connective tissue, osteoblast and osteocyte populations after healing [3]. These markers provide insight into remodelling activity and are used in research to evaluate interventions.

Animal and in vitro evidence

The evidence block for this page does not include animal-only or in vitro studies. The studies cited are clinical (human) investigations: a cross-sectional case-control study [1], an ongoing clinical trial [2], and a clinical study [3]. Where animal or in vitro data exist in the broader literature, they are not represented in the sources provided here.

Clinical implications and ongoing research

Research into bone remodelling continues to explore nutritional, molecular, and pharmacological factors. The vitamin K study highlights the importance of nutrient-specific effects in skeletal fragility [1]. The microRNA study aims to identify markers of response to anabolic and dual-action therapies [2]. The PTH sinus augmentation study investigates bone regeneration in a localized graft model [3]. Together, these studies contribute to understanding of remodelling processes and potential therapeutic targets.

If you are reading this for personal health reasons

The materials and information described here are sold for laboratory research use only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Vitamin K Status and Skeletal Fragility: Differential Associations of Osteocalcin Carboxylation States with Bone Strength, Geometry and Microarchitecture
• [2] MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis
• [3] Radiographical, Histomorphometrical and Biomarker Analysis After Maxillary Sinus Augmentation Utilizing Xenograft Particulate Bone Graft Mixed With Parathyroid Hormone